Entasis Forward-looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Entasis Therapeutics Holdings Inc. (Exact name of Registrant as specified in its charter) Delaware . WALTHAM, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today its second quarter 2020 financial results and provided a business update. Entasis Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update. Entasis Therapeutics Reports Second Quarter 2020 Financial Results and Business Update. We then achieved a second key milestone in September with the advancement of zoliflodacin, a novel antibiotic for the treatment of uncomplicated gonorrhea, into a Phase 3 registration trial.”, Dr. Perros added, “To further drive our strategic initiatives, we bolstered our leadership team through the additions of several key members of management. Entasis Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Business Update. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. 2018. Aug 06, 2020. Exhibit 99.1 Entasis Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Business Update WALTHAM, Mass., November 5, 2020 (GLOBE NEWSWIRE) – Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on … Company Contact Kyle Dow Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.com, Investor Relations ContactsTram Bui / James SaliernoThe Ruth Group(646) 536-7035 / 7028tbui@theruthgroup.comjsalierno@theruthgroup.com, Media ContactKirsten ThomasThe Ruth Group(508) 280-6592kthomas@theruthgroup.com. 0.00. Entasis Therapeutics Reports Full Year 2019 Financial Results and Business Update Email Print Friendly Share March 11, 2020 16:05 ET | Source: Entasis Therapeutics Holdings Inc. “2019 marked a pivotal year for the Company as we made great strides both advancing our clinical programs and strengthening our leadership team,” stated Manos Perros, President and Chief Executive Officer of Entasis Therapeutics. Promoted If you’re looking to trade Entasis Therapeutics Holdings, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. PDF. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. 2019 Annual Report and Form 10K. Work for Entasis Therapeutics Holdings Inc.? Entasis Therapeutics Holdings Inc. has reached its limit for free report views. 2020-11-05: EX-99.1: Entasis Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Business Update. WALTHAM, Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. ( ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its second quarter financial results ended June 30, 2019 and provided a business update. Create global change by contributing to groundbreaking science in the antibacterial space at Entasis. Read full article. US:ETTX / Entasis Therapeutics Holdings Inc. - SEC Filings, 10K, 8K, Annual Report, Proxy Statement Security ETTX / Entasis Therapeutics Holdings Inc. (293614103) General and administrative expenses were $13.8 million for the year ended December 31, 2019, compared to $10.2 million for the year ended December 31, 2018. ... At Entasis, we discover and develop novel antibacterials to address the serious medical need posed by multi-drug resistant bacterial infections." The increase was driven by costs associated with additional headcount, director and officer insurance costs, and VAT and other taxes associated with the milestone revenue from our collaboration with Zai Lab Limited. We appointed two biopharmaceutical veterans, Dr. David Altarac as Chief Medical Officer and Eric Kimble as Chief Commercial Officer, who combined have nearly 50 years of industry experience. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Entasis Therapeutics Holdings Inc.. Additionally, we strengthened our Board of Directors through the additions of David Meek as the Chairman of the Board and Dr. Howard Meyer. Entasis Therapeutics to Participate in Upcoming Healthcare Conferences. Entasis reported revenue of $5.0 million and grant income of $5.3 million for the year ended December 31, 2018, compared to no revenue and $1.4 million of grant income for the year ended December 31, 2017. Nov 5, 2020. Entasis Therapeutics was established in 2015 as a spin-out from and with initial funding from AstraZeneca, and all rights to AstraZeneca’s industry-leading discovery and early development small-molecule anti-infectives portfolio. Sep 10, 2020. In return, the Company has provided them with exclusive commercial rights in low-income and select middle-income countries. Entasis Therapeutics Reports Full Year 2019 Financial Results and Business Update Published. 2019-06-13 sec.gov - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2019 ENTASIS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38670 82-4592913 … Report of unscheduled material events or corporate event. The Company strengthened its management team with the appointment of key industry leaders including Eric Kimble as Chief Commercial Officer to build and oversee the Company’s global commercialization strategy and product launch initiatives. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support 29, 2019 7:33 AM ET Entasis Therapeutics Holdings Inc. (ETTX) By: Mamta Mayani , SA News Editor Entasis Therapeutics (NASDAQ: ETTX ): … In November, the Company also appointed David Altarac, M.D., MPA as Chief Medical Officer. Q3 2020 (Millions USD) Revenue. Our Story. Entasis Therapeutics strives towards global advancement by addressing the critical threat of multi-drug resistant bacteria. Entasis Therapeutics Holdings Inc. has reached its limit for free report views. In September, the Global Antibiotic Research and Development Partnership (GARDP) initiated the global Phase 3 registration trial of zoliflodacin for the treatment of uncomplicated gonorrhea. A data readout from the Phase 3 registration trial is expected in 2021. Earnings results for Entasis Therapeutics (NASDAQ:ETTX) Entasis Therapeutics Holdings Inc. is estimated to report earnings on 03/17/2021. Entasis Therapeutics was established in 2015 as a spin-out from and with initial funding from AstraZeneca, and all rights to AstraZeneca’s industry-leading discovery and early development small-molecule anti-infectives portfolio. WALTHAM, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today its first quarter 2020 financial results and provided a business update.“We are very pleased with the continued progress made during the first quarter of 2020, despite … The Company reported a net loss of $43.9 million for the year ended December 31, 2019, compared to a net loss of $33.0 million for the year ended December 31, 2018. For more information, visit www.entasistx.com. Entasis Therapeutics Holdings Inc. Consolidated Statements of Operations. Full Year Financial Results. Mr. Kimble, who was appointed in April, has over 25 years of commercial leadership experience in sales, marketing and commercial strategy, and product launches from Cubist Pharmaceuticals, Biogen Inc. and Merck & Co. Entasis Therapeutics Announces $25 Million Private Placement. — Ruben Tommasi, Chief Scientific Officer ©2021 Entasis Therapeutics Inc. Le W, Su X, Lou X, Li X, Gong X, Wang B, Genco CA, Mueller JP and Rice PA . Upgrade your company profile to unlock all of your annual report content on AnnualReports.com. Form 10K (HTML) Upgrade your company profile to unlock all of your annual report content on AnnualReports.com. We have assembled a world-class team with a global calling to work on these life-saving, long lasting antibacterial therapies. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). The increase in net loss was primarily due to increases in development expense and general and administrative expense and a decrease in other income, partially offset by the aforementioned increase in revenue year over year. These forward-looking statements are based on Entasis’ expectations and assumptions as of the date of this press release. This may not be consistent with full year annual report figures. © 2021 GlobeNewswire, Inc. All Rights Reserved. Dr. Altarac is a recognized industry R&D leader and brings broad experience, most recently as senior vice president and head of global regulatory affairs, global drug safety and R&D quality and compliance at Shire Plc. Net Income-11,133,000.00. We offer a dynamic and diverse work environment in spacious modern laboratories at the Gatehouse Park BioHub in Waltham, MA. Antimicrobial Agents and Chemotherapy (2020) Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its third quarter financial results for the period ended September 30, 2019 and provided a business update. Nov 14, 2019 7:30AM EST. Since receiving our initial funding from AstraZeneca, we have raised another $81.9 million gross proceeds from equity financings from a number of U.S. and European healthcare specialist investment firms, including Clarus Lifesciences, Novo Holdings A/S, Frazier Life Sc… Entasis reported revenue of $7.0 million and grant income of $2.3 million for the year ended December 31, 2019, compared to revenue of $5.0 million and $5.3 million of grant income for the year ended December 31, 2018. “I’m pleased to report substantial progress across a number of areas of the … 8-K: 0001104659-20-122481.pdf. August 12, 2019, 4:30 AM. In June, the Company reported preliminary results from its randomized, double-blind, placebo-controlled Phase 1 clinical study of ETX0282, an oral beta-lactamase inhibitor, being developed to combat multidrug-resistant, In December the Company selected ETX0462 as a clinical candidate from its non-b-lactam penicillin binding protein inhibitor (NBP) program. Entasis Therapeutics (NASDAQ:ETTX): Q1 GAAP EPS of -$0.99.Cash, cash equivalents and investments of $74.56MPress Release Entasis Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update Published. ETX0282CPDP is partly funded by CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), ... ©2021 Entasis Therapeutics. The Company believes its current cash position provides a runway into the fourth quarter of 2020. Entasis Therapeutics Reports First Quarter 2020 Financial Results and Business Update Email Print Friendly Share May 07, 2020 16:05 ET | Source: Entasis Therapeutics Holdings Inc. In April, we launched the global ATTACK (Acinetobacter Treatment Trial Against Colistin) Phase 3 registration trial, evaluating a fixed-dose combination of sulbactam plus durlobactam (SUL-DUR) as a potential treatment for carbapenem-resistant Acinetobacter baumannii infections. 2834 . Entasis Therapeutics reports FY results Mar. WALTHAM, Mass., March 11, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its full year 2019 financial results and business highlights. Since receiving our funding from AstraZeneca, we have raised $81.9 million in gross proceeds from equity financings from several U.S. and European healthcare specialist … WALTHAM, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today its first quarter 2020 financial results and provided a business update. Entasis Therapeutics Holdings is a smaller company with a market capitalization of US$100m, so it may still be flying under the radar of many institutional investors. Entasis Therapeutics to Participate in Upcoming Healthcare Investor Conferences. Research and development expenses were $40.2 million for the year ended December 31, 2019, compared to $33.0 million for the year ended December 31, 2018. We are extremely excited to build upon our strong 2019 performance and look forward to ATTACK and zoliflodacin Phase 3 registration trial data readouts.”. The revenue in 2019 was attributable to milestones achieved pursuant to the Company’s collaboration agreement with Zai Lab (Shanghai) Co., Ltd. Forward-looking statements contained in this announcement are made as of this date, and except as required by law, Entasis assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis is working to secure the future of antibacterial effectiveness. “We are very pleased with the continued progress made during the first … Mar 11, 2020 4:05PM EDT. Unaudited (in thousands, except share and per share data) Year Ended December 31, 2019. The randomized, open label trial will enroll approximately 1,000 adults with urogenital gonorrhea at clinical trial sites in the United States and internationally and will assess the safety and efficacy of zoliflodacin versus the combination of azithromycin and ceftriaxone, the current standard of care. About EntasisEntasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Aug 05, 2020. Entasis Therapeutics Holdings Inc is primarely in the business of pharmaceutical preparations. These and other risks and uncertainties are described more fully in the Entasis’ filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Entasis is initially developing ETX0282CPDP, the combination of ETX0282 and cefpodoxime, for the treatment of UTI caused by drug-resistant Enterobacteriaceae.
Joker Real 4k, Rakitić Fifa 21, Fda Vaccine Guidance, Gesundheitsamt Darmstadt Formulare, Heat Vs Spurs 2014, Us-wahl Live Ticker Ntv, Der Pass 2 Zdf, Tanger Outlets Investors, Mkoa Wa Kilimanjaro Na Wilaya Zake,